Posted 10/25/22; updated 10/27/22
Summary
Multiple exciting conference are taking place over the next two months!
ASN Kidney Week takes place Nov 3-6 (abstracts were released Oct 14)
AASLD The Liver Meeting takes place Nov 4-8 (abstracts were released Oct 21)
CTAD takes place Nov 29-Dec 2 (abstracts will be released Dec 2)
Watch as we add more companies into these conference tables including info about presentation
See our forum for a more in depth table after subscribing. Learn more here.
The remainder of 2022 includes many exciting biomedical conferences where smid-cap biopharma companies can present data on ongoing trials, and possibly new topline data! At BPIQ we scour our database to determine which biopharmas are presenting new data and provide additional info on these presentations and assets.
Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. Abstracts for ASN Kidney Week and ASSLD The Liver Meeting were already released, and CTAD abstracts will be released December 2. Poster session data will be embargoed until November 29, but data in oral presentations is embargoed until Dec 2. See Tables 1 and 2 (for Kidney Week and The Liver Meeting respectively) for info on companies presenting clinical data and see our forum for additional info including stock moves on the dates companies announced involvement. We added Table 3 on 10/27/2022 to include CTAD presentations!.
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.
To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting clinical trial updates at Kidney Week, The Liver Meeting, and CTAD (coming soon). Table 1 lists those companies in our BPIQ database that are presenting clinical update(s) at Kidney Week and Table 2 is those companies presenting clinical updates at The Liver Meeting. Table 3 includes companies presenting clinical trials at CTAD 2022 (added 10/27/22). These tables include companies presenting clinical data; while other companies in our database are also presenting preclinical we focus on clinical results.
See Tables 1, 2, & 3 for introductory info on these companies and keep an eye out for more details to come surrounding presentation data.
Table 1. BPIQ.com smid-cap biopharma companies presenting clinical updates at Kidney Week
Table 2. BPIQ.com smid-cap biopharma companies presenting clinical updates at The Liver Meeting
Table 3. BPIQ.com small - large cap* biopharma companies presenting clinical updates at CTAD
*Several large cap companies presenting at CTAD are included here because previous trial data reported from these companies moved smid-cap AD biopharmas substantially
The question for biopharma investors now with respect to these conferences is which stocks or groups of stocks are likely to move upon the release of abstract, poster, oral presentation, or associated investor meeting. We plan to continue to analyze the current trial data from liver and kidney companies as well as the abstracts of Alzheimer's companies, once released, and plan to update this information on BPIQ.com. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of our most exciting future medicines. For investors, these companies represent an exciting opportunity for further diligence and possible investment.
See our forum post for a more in depth table after subscribing. Learn more here.
#ALGS #ALG000184 #ALG055009 #CBAY #Seladelpar #ALBO #Odevixibat #AKBA #Vadadustat #ARDX #Tenapanor #CINC #Baxdrostat #ELDN #Tegoprubart #KDNY #Atrasentan #BION1301 #PROK #REACT #TCDA #Veverimer
This article is NOT legal, investment or tax advice. Please do your own diligence before making any investments.
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Article history:
Originally posted 10/25/22